Muscle Capillarization and Sarcopenia

Sarcopenia Clinical Trial

Official title:

Increasing Muscle Capillarization to Enhance Responses to Strength Training in Sarcopenia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03984994
• Other study ID #: HP-00086001
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 1, 2021
• Est. completion date: April 30, 2024

Study information

• Verified date: January 2024
• Source: Baltimore VA Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aging is associated with a loss of muscle mass, termed sarcopenia, that reduces mobility, decreases physical function and accelerates progression of other age-related disorders. This study is designed to determine whether increasing skeletal muscle capillarization through aerobic exercise will enhance muscular adaptations to strength training in older adults with sarcopenia.

Description:

Sarcopenia, or the aging-related loss of muscle mass, affects a large number of older adults. The presence of sarcopenia is associated with physical disability, poor quality of life, and all-cause mortality, in part because sarcopenic adults have low muscle skeletal muscle capillarization and may lack the adequate perfusion needed to maintain muscle mass and function. This study will test the effects of increasing skeletal muscle capillarization through aerobic exercise training on responses to resistance training in older adults. Eligible participants will be randomized to one of two groups, resistance training preceded by aerobic exercise training (AEX-RT), or resistance training followed by aerobic exercise training (RT-AEX). Participants in the AEX-RT group will undergo 3 months of aerobic exercise training to increase skeletal muscle capillarization, followed by 3 months of resistance training. Participants in the RT-AEX group will undergo 3 months of resistance training, followed by 3 months of aerobic exercise training. Before and after the interventions, participants will undergo assessments of muscle size, strength, and capillarization, as well as assessments of physical function.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 32
• Est. completion date: April 30, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years to 88 Years

Eligibility

Inclusion Criteria:

• Body Mass Index = 18-32.5 kg/m2

• Non-smoker

• Presence of at least moderate sarcopenia (low muscle mass per unit body height)

Exclusion Criteria:

• Diagnosis of diabetes, cancer, pulmonary or renal disease

• Physical impairment preventing exercise

• Recent history of exercise training

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Other:
• Aerobic exercise training
3 months of center-based, supervised treadmill exercise
• Strength training
3 months of center-based, supervise strength training

Locations

Country	Name	City	State
United States	University of Maryland, Baltimore & Baltimore VA Medical Center	Baltimore	Maryland
United States	University of Maryland	College Park	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Baltimore VA Medical Center	University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skeletal muscle capillarization	Change in the number of capillaries per unit of skeletal muscle tissue	6 months
Primary	Muscle volume	Change in the size of the thigh muscles	6 months
Secondary	Skeletal muscle fiber size	Change in the cross-sectional size of individual thigh skeletal muscle fibers	6 months
Secondary	Muscle strength	Change in the strength/force produced by skeletal muscles of the thigh	6 months